Activity of isoflavone in managing polycystic ovary syndrome symptoms (Review)

Raihanah,Cut; Sukrasno,Sukrasno; Kurniati,Neng Fisheri

doi:10.3892/br.2024.1768

Activity of isoflavone in managing polycystic ovary syndrome symptoms (Review)

Authors:
- Cut Raihanah
- Sukrasno Sukrasno
- Neng Fisheri Kurniati
View Affiliations

Affiliations: Department of Pharmaceutical Biology, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia, Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia
Published online on: March 21, 2024 https://doi.org/10.3892/br.2024.1768
Article Number: 80
Copyright: © Raihanah et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycystic ovary syndrome (PCOS), a hormonal and metabolic disorder manifested in women of reproductive age, is still being treated using drugs with side effects. As an alternative to these drugs, isoflavone, also identified as phytoestrogen, has anti‑PCOS activity. Isoflavone can help relieve PCOS symptoms by lowering the level of testosterone, which causes hyperandrogenism, thereby normalizing the menstrual cycle and restoring normal ovarian morphology. Furthermore, isoflavone influences the improvement of the metabolic profile, which changes because of PCOS, as well as the reduction of inflammatory markers and oxidative stress. However, both significant and non‑significant results have been generated on the activity of isoflavones in PCOS. The present review aims to discuss the existing literature on the effect of isoflavone on PCOS symptoms based on in vivo and clinical trial studies.

View Figures

View References

1	Barbosa G, de Sá L, Rocha D and Arbex A: Polycystic ovary syndrome (PCOS) and infertility. Open J Endocr Metab Dis. 6:58–65. 2016.
2	Lentscher JA and Decherney AH: Clinical presentation and diagnosis of polycystic ovarian syndrome. Clin Obstet Gynecol. 64:3–11. 2021.PubMed/NCBI View Article : Google Scholar
3	Ma X, Li X, Ma L, Chen Y and He S: Soy isoflavones alleviate polycystic ovary syndrome in rats by regulating NF-κB signaling pathway. Bioengineered. 12:7204–7212. 2021.PubMed/NCBI View Article : Google Scholar
4	Harris HR, Titus LJ, Cramer DW and Terry KL: Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study. Int J Cancer. 140:285–291. 2017.PubMed/NCBI View Article : Google Scholar
5	Ashraf S, Nabi M, Rasool SUA, Rashid F and Amin S: Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: A review. Egypt J Med Hum Genet. 20(25)2019.
6	Smet ME and McLennan A: Rotterdam criteria, the end. Australas J Ultrasound Med. 21:59–60. 2018.PubMed/NCBI View Article : Google Scholar
7	Reid SP, Kao CN, Pasch L, Shinkai K, Cedars MI and Huddleston HG: Ovarian morphology is associated with insulin resistance in women with polycystic ovary syndrome: A cross sectional study. Fertil Res Pract. 3(8)2017.PubMed/NCBI View Article : Google Scholar
8	Rodriguez Paris V and Bertoldo MJ: The mechanism of androgen actions in PCOS etiology. Med Sci (Basel). 7(89)2019.PubMed/NCBI View Article : Google Scholar
9	Kamboj A, Verma D, Sharma D, Pant K, Pant B and Kumar V: A molecular docking study towards finding herbal treatment against polycystic ovary syndrome (PCOS). Int J Recent Technol Eng. 8:38–41. 2019.
10	Gayathri K, Supriya V and Palaniappan N: Nutritional composition and sensory evaluation of phytoestrogen-rich supplement for women with PCOS. Int J Nutr Pharmacol Neurol Dis. 11:303–308. 2021.
11	Shehab NG, Anbar HS, Alrouby NM, Abouelalamin A, Lutfi L, Allo IT and Elayoty SM: New alternative herbal remedies for treatment of letrozole-induced polycystic ovary syndrome in rats. J Appl Pharm Sci. 13:163–179. 2023.
12	Moini Jazani A, Nasimi Doost Azgomi H, Nasimi Doost Azgomi A and Nasimi Doost Azgomi R: A comprehensive review of clinical studies with herbal medicine on polycystic ovary syndrome (PCOS). DARU. 27:863–877. 2019.PubMed/NCBI View Article : Google Scholar
13	Jang HH, Lee YM, Choe JS and Kwon O: Validation of soy isoflavone intake and its health effects: A review of the development of exposure biomarkers. Nutr Res Pract. 15:1–11. 2021.PubMed/NCBI View Article : Google Scholar
14	Manzar N, Khan AS, Fatima N, Nisa M, Ahmad MH, Afzal MI, Saeed HFU, Imran M, Anjum FM and Arshad MS: Exploring the prophylactic role of soy isoflavones against polycystic ovarian syndrome. Food Sci Nutr. 9:4738–4744. 2021.PubMed/NCBI View Article : Google Scholar
15	Gómez-Zorita S, González-Arceo M, Fernández-Quintela A, Eseberri I, Trepiana J and Portillo MP: Scientific evidence supporting the beneficial effects of isoflavones on human health. Nutrients. 12(3853)2020.PubMed/NCBI View Article : Google Scholar
16	Křížová L, Dadáková K, Kašparovská J and Kašparovský T: Isoflavones. Molecules. 24(1076)2019.PubMed/NCBI View Article : Google Scholar
17	Leonard LM, Choi MS and Cross TL: Maximizing the estrogenic potential of soy isoflavones through the gut microbiome: Implication for cardiometabolic health in postmenopausal women. Nutrients. 14(553)2022.PubMed/NCBI View Article : Google Scholar
18	Desmawati D and Sulastri D: Phytoestrogens and their health effect. Open Access Maced J Med Sci. 7:495–499. 2019.PubMed/NCBI View Article : Google Scholar
19	Xu XL, Deng SL, Lian ZX and Yu K: Estrogen receptors in polycystic ovary syndrome. Cells. 10(459)2021.PubMed/NCBI View Article : Google Scholar
20	Rajan RK, Kumar MSS and Balaji B: Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism. Pharm Biol. 55:242–251. 2017.PubMed/NCBI View Article : Google Scholar
21	Abbasian Z, Barmak MJ, Barazesh F, Ghavamizadeh M and Mirzaei A: Therapeutic efficacy of Trifolium pratense L. on letrozole induced polycystic ovary syndrome in rats. Plant Sci Today. 7:501–507. 2020.
22	Xu J, Dun J, Yang J, Zhang J, Lin Q, Huang M, Ji F, Huang L, You X and Lin Y: Letrozole rat model mimics human polycystic ovarian syndrome and changes in insulin signal pathways. Med Sci Monit. 26(e923073)2020.PubMed/NCBI View Article : Google Scholar
23	Yang AM, Cui N, Sun YF and Hao GM: Letrozole for female infertility. Front Endocrinol (Lausanne). 12(676133)2021.PubMed/NCBI View Article : Google Scholar
24	Rajaei S, Alihemmati A and Abedelahi A: Antioxidant effect of genistein on ovarian tissue morphology, oxidant and antioxidant activity in rats with induced polycystic ovary syndrome. Int J Reprod Biomed. 17:11–22. 2019.PubMed/NCBI View Article : Google Scholar
25	Alivandi Farkhad S and Khazali H: Therapeutic effects of isoflavone-aglycone fraction from soybean (Glycine max L. Merrill) in rats with estradiol valerate-induced polycystic ovary syndrome as an inflammatory state. Gynecol Endocrinol. 35:1078–1083. 2019.PubMed/NCBI View Article : Google Scholar
26	Ramadoss M, Vijayaraman M and Subbiah AJ: Estradiol valerate dose determination for PCOS induction. Int J Pharm Biol Sci. 9:1131–1136. 2019.
27	Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 19:41–47. 2004.PubMed/NCBI View Article : Google Scholar
28	Li W, Hu H, Zou G, Ma Z, Liu J and Li F: Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women. Medicine (Baltimore). 100(e26049)2021.PubMed/NCBI View Article : Google Scholar
29	Blouin K, Boivin A and Tchernof A: Androgens and body fat distribution. J Steroid Biochem Mol Biol. 108:272–280. 2008.PubMed/NCBI View Article : Google Scholar
30	Homburg R: Androgen circle of polycystic ovary syndrome. Hum Reprod. 24:1548–1555. 2009.PubMed/NCBI View Article : Google Scholar
31	Dumesic DA, Abbott DH, Sanchita S and Chazenbalk GD: Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective. Curr Opin Endocr Metab Res. 12:41–48. 2020.PubMed/NCBI View Article : Google Scholar
32	Rasmussen MK, Ekstrand B and Zamaratskaia G: Regulation of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase: A review. Int J Mol Sci. 14:17926–17942. 2013.PubMed/NCBI View Article : Google Scholar
33	Kater CE, Giorgi RB and Costa-Barbosa FA: Classic and current concepts in adrenal steroidogenesis: A reappraisal. Arch Endocrinol Metab. 66:77–87. 2022.PubMed/NCBI View Article : Google Scholar
34	Murri M, Luque-Ramı´rez M, Insenser M, Ojeda-Ojeda M and Escobar-Morreale HF: Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Hum Reprod Update. 19:268–288. 2013.PubMed/NCBI View Article : Google Scholar
35	Karabulut AB, Cakmak M, Kiran RT and Sahin I: Oxidative stress status, metabolic profile and cardiovascular risk factors in patients with polycystic ovary syndrome. Med Science. 1:27–34. 2012.
36	Diamanti-Kandarakis E, Piperi C, Kalofoutis A and Creatsas G: Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 62:37–43. 2005.PubMed/NCBI View Article : Google Scholar
37	Isık H, Aynıoglu O, Tımur H, Sahbaz A, Harma M, Can M, Guven B, Alptekin H and Kokturk F: Is Xanthine oxidase activity in polycystic ovary syndrome associated with inflammatory and cardiovascular risk factors? J Reprod Immunol. 116:98–103. 2016.PubMed/NCBI View Article : Google Scholar
38	Mohammadi M: Oxidative stress and polycystic ovary syndrome: A brief review. Int J Prev Med. 10(86)2019.PubMed/NCBI View Article : Google Scholar
39	Enechukwu CI, Onuegbu AJ, Olisekodiaka MJ, Eleje GU, Ikechebelu JI, Ugboaja JO, Amah UK, Okwara JE and Igwegbe AO: Oxidative stress markers and lipid profiles of patients with polycystic ovary syndrome in a Nigerian tertiary hospital. Obstet Gynecol Sci. 62:335–343. 2019.PubMed/NCBI View Article : Google Scholar
40	Fathi FH: Biomarkers of oxidative stress in polycystic ovary disorder. Ann Coll Med Mosul. 41:112–116. 2019.
41	Jamilian M and Asemi Z: The effects of soy isoflavones on metabolic status of patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 101:3386–3394. 2016.PubMed/NCBI View Article : Google Scholar
42	Karamali M, Kashanian M, Alaeinasab S and Asemi Z: The effect of dietary soy intake on weight loss, glycaemic control, lipid profiles and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: A randomised clinical trial. J Hum Nutr Diet. 31:533–543. 2018.PubMed/NCBI View Article : Google Scholar
43	Jamilian M and Sahebkashaf R: Metabolic response to soy supplementation in women with polycystic ovary syndrome. J Arak Uni Med Sci. 20:14–23. 2017.
44	Herman R, Sever MJ, Janež A and Vita D: Interplay between oxidative stress and chronic inflammation in PCOS: the role of genetic variability in PCOS risk and treatment responses. IntechOpen. Ch 8:2020.
45	Amanat S, Ashkar F, Eftekhari MH, Tanideh N, Doaei S, Gholamalizadeh M, Koohpeyma F and Mokhtari M: The effect of genistein on insulin resistance, inflammatory factors, lipid profile, and histopathologic indices in rats with polycystic ovary syndrome. Clin Exp Reprod Med. 48:236–244. 2021.PubMed/NCBI View Article : Google Scholar
46	Yu J, Bi X, Yu B and Chen D: Isoflavones: Anti-inflammatory benefit and possible caveats. Nutrients. 8(361)2016.PubMed/NCBI View Article : Google Scholar
47	Khani B, Mehrabian F, Khalesi E and Eshraghid A: Effect of soy phytoestrogen on metabolic and hormonal disturbance of women with polycystic ovary syndrome. J Res Med Sci. 16:297–302. 2011.PubMed/NCBI
48	Saadia Z: Follicle stimulating hormone (LH: FSH) ratio in polycystic ovary syndrome (PCOS)-obese vs. non-obese women. Med Arch. 74:289–293. 2020.PubMed/NCBI View Article : Google Scholar
49	Madnani N, Khan K, Chauhan P and Parmar G: Polycystic ovarian syndrome. Indian J Dermatol Venereol Leprol. 79:310–321. 2013.PubMed/NCBI View Article : Google Scholar
50	Ekambaram G, Sampath Kumar SK and Joseph LD: Comparative study on the estimation of estrous cycle in mice by visual and vaginal lavage method. J Clin Diagnostic Res. 11:AC05–AC07. 2017.PubMed/NCBI View Article : Google Scholar
51	Ajayi AF and Akhigbe RE: Staging of the estrous cycle and induction of estrus in experimental rodents: An update. Fertil Res Pract. 6(5)2020.PubMed/NCBI View Article : Google Scholar
52	Nallathambi A and Bhargavan R: Regulation of estrous cycle by Cynodon dactylon in letrozole induced polycystic ovarian syndrome in Wistars albino rats. Anat Cell Biol. 52:511–517. 2019.PubMed/NCBI View Article : Google Scholar
53	Shilpa N, Itagi V and Rani R: A study of hemoglobin concentration in different phases of menstrual cycle. Int J Physiol. 6:90–94. 2018.
54	Jahan S, Abid A, Khalid S, Afsar T, Qurat-Ul-Ain Shaheen G, Almajwal A and Razak S: Therapeutic potentials of quercetin in management of polycystic ovarian syndrome using letrozole induced rat model: A histological and a biochemical study. J Ovarian Res. 11(26)2018.PubMed/NCBI View Article : Google Scholar
55	Teixeira CP, Florencio-Silva R, Sasso GRS, Carbonel AAF, Simões RS and Simões MJ: Soy isoflavones protect against oxidative stress and diminish apoptosis in ovary of middle-aged female rats. Gynecol Endocrinol. 35:586–590. 2019.PubMed/NCBI View Article : Google Scholar
56	Khezri S, Alihemmati A and Abedelahi A: Genistein blunted detrimental effects of polycystic ovary syndrome on the ovarian tissue of rats by improving follicular development and gonadotropin secretion. JBRA Assist Reprod. 26:379–386. 2022.PubMed/NCBI View Article : Google Scholar
57	Ali SE, El Badawy SA, Elmosalamy SH, Emam SR, Azouz AA, Galal MK, Abd-Elsalam RM, Issa MY and Hassan BB: Novel promising reproductive and metabolic effects of Cicer arietinum L. extract on letrozole induced polycystic ovary syndrome in rat model. J Ethnopharmacol. 278(114318)2021.PubMed/NCBI View Article : Google Scholar
58	Geethika L and Okada S: Investigating the effect of soy isoflavones on improving polycystic ovary syndrome hallmarks liyanage. Soy Protein Research. 21:90–94. 2018.